Fortrea Holdings Inc. (FTRE1) Stock Price & Analysis
FTRE1 Stock Chart & Stats
- Day’s Range
- MXN 373.00 - MXN 373.00
- 52-Week Range
- MXN 373.00 - MXN 373.00
- Previous Close
- MXN 373.00
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 38.60B
- Enterprise Value
- MXN 2.92B
- Total Cash (Recent Filing)
- MXN 220.60M
- Total Debt (Recent Filing)
- MXN 1.12B
- Price to Earnings (P/E)
- ―
- Beta
- 0.07
- Next Earnings
- Mar 15, 2027 (Est.)
- EPS Estimate
- 3.85
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Cash Generation
Positive operating and free cash flow provide internal funding for debt reduction, investment and business execution even while reported net income remains negative. Continued cash conversion would improve financial resilience, though sustaining it depends on cost discipline and stable working capital.
Bookings And Demand
Bookings above revenue indicate customer demand is supporting future workload, while growth in biotech activity and broader opportunities across sponsors expand Fortrea’s commercial base. Sustained awards can help restore revenue growth and improve operating leverage over coming quarters.
Margin Improvement
Higher adjusted EBITDA and margin show that portfolio mix, cost management and efficiency initiatives are beginning to translate into better earnings power. If revenue growth resumes, these operational gains could support further operating leverage toward management’s mid-teens margin objective.
Bears Say
Revenue Contraction
Ongoing top-line contraction limits the benefits of cost reductions and makes margin recovery less durable. Lower revenue also reduces utilization and operating leverage, leaving Fortrea dependent on renewed service-fee growth to convert improving demand into consistent profitability.
Elevated Leverage
Leverage remains a material constraint on financial flexibility despite recent improvement. Debt service and variable-rate exposure can absorb cash that might otherwise fund growth, while the acquisition-related increase makes continued cash generation and deleveraging important to balance-sheet stability.
Backlog Quality And Cancellations
The backlog adjustment and elevated cancellations weaken the reliability of contracted work as an indicator of future revenue. They suggest that headline backlog requires ongoing portfolio validation, potentially delaying conversion and making near-term growth and capacity planning less predictable.
Fortrea Holdings Inc. News
Court Dismisses Fortrea Holdings (FTRE) Securities Lawsuit Over Spin-Off Cost and Backlog Claims
A federal judge has dismissed a securities lawsuit against Fortrea Holdings Inc. ($FTRE), ending, at least at the trial court level, shareholder claims that the clinical research company misled investors
FTRE1 FAQ
What was Fortrea Holdings Inc.’s price range in the past 12 months?
What is Fortrea Holdings Inc.’s market cap?
When is Fortrea Holdings Inc.’s upcoming earnings report date?
How were Fortrea Holdings Inc.’s earnings last quarter?
Is Fortrea Holdings Inc. overvalued?
Does Fortrea Holdings Inc. pay dividends?
What is Fortrea Holdings Inc.’s EPS estimate?
How many shares outstanding does Fortrea Holdings Inc. have?
What happened to Fortrea Holdings Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Fortrea Holdings Inc.?
What is the TipRanks Smart Score and how is it calculated?
Fortrea Holdings Inc. Stock Smart Score
Company Description
Fortrea Holdings Inc.
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Anshul Thakral
- Employees
- 14,000
- Website
- www.fortrea.com
- Address
- 8 Moore Drive, Durham, NC, 27713, US
Fortrea Holdings Inc. (FTRE1) Earnings & Revenues
FTRE1 Company Deck
FTRE1 Earnings Call
Earnings Call SentimentPositive
The call was broadly optimistic. Fortrea reported stronger bookings, improved profitability, positive cash flow, better working capital, raised full-year guidance and expanding demand across biotech, biopharma and China. The main concerns were the year-over-year revenue decline, the $558 million backlog adjustment, slightly elevated cancellations, a projected fourth-quarter revenue slowdown, ongoing compensation investments and still-elevated leverage. Management characterized the business as being in recovery and focused on converting improving demand into sustainable growth and margin expansion.
View all MX:FTRE1 earnings summariesFTRE1 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 0 | 12 | 0 |
| Technical Analysis | 0 | 0 | 0 |
| Moving Averages | 0 | 12 | 0 |